A PHASE3 study (NCT05425940) investigating Atezolizumab in combination with XL092 for participants with Metastatic Colorectal Cancer reached primary completion on 2026-06-16. This trial compares the combination therapy against regorafenib in patients who have progressed on or are intolerant to standard-of-care therapy.
Background
Atezolizumab is being investigated in a PHASE3 study for participants with Metastatic Colorectal Cancer. The study focuses on patients with microsatellite stable/microsatellite instability low (MSS/MSI-low) mCRC who have progressed during, after, or are intolerant to standard-of-care (SOC) therapy.
Trial design
The study, identified as NCT05425940, is a PHASE3 trial that has enrolled 901 participants with Metastatic Colorectal Cancer. The trial's primary purpose is to evaluate XL092 in combination with atezolizumab versus regorafenib. This comparison is for participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer who have progressed during, after, or are intolerant to standard-of-care (SOC) therapy.
What this means
The primary completion of this PHASE3 study indicates that the main data collection period for the trial's primary endpoint has concluded. This is a significant step in the clinical development process for XL092 plus atezolizumab in Metastatic Colorectal Cancer, moving the trial closer to the analysis and potential reporting of results. The study aims to provide insights into the efficacy and safety of the combination therapy compared to regorafenib in this specific patient population.
Source
This information was sourced from ClinicalTrials.gov, documenting the primary completion of trial NCT05425940 on 2026-06-16. The study details are available on clinicaltrials.gov.